TOCA News and Press, Tocagen From 11/12/19

Tocagen (NASDAQ: TOCA ): Q3 GAAP EPS of -$0.78 misses by $0.06 . More news on: Tocagen Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Continuing with the series of articles on gene therapy, this article will discuss the various delivery methods for gene therapies with a focus on viral vectors. What is transgene? A transgene is a new therapeutic DNA segment that is to be inserted into the host cell. In addition to the g...

SAN DIEGO , Nov. 8, 2019 /PRNewswire/ --  Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced that the Company presented data from the Toca 6 Phase 1b study of Toca 511 and Toca FC in patients with non-CNS tumors at the Society fo...

SAN DIEGO , Nov. 6, 2019 /PRNewswire/ --  Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced it will report its third quarter 2019 financial results and business progress on Tuesday, November 12, 2019 , after the close of the U.S. ...

SAN DIEGO , Oct. 3, 2019 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced a restructuring to focus its resources on the clinical development of Toca 511 and Toca FC. Tocagen will reduce its workforce by appro...

Denali Therapeutics (NASDAQ: DNLI ) initiated with Buy rating and $35 (84% upside) price target at Nomura Instinet. More news on: Denali Therapeutics Inc., Intuitive Surgical, Inc., ACADIA Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Gainers:  Sintx Technologies (NASDAQ: SINT ) +71% . Ruhnn Holding Limited (NASDAQ: RUHN ) +29% . Jaguar Health (NASDAQ: JAGX ) +19% . T2 Biosystems (NASDAQ: TTOO ) +15% . OncoCyte Corporation (NYSEMKT: OCX ) +13% . Libbey (NYSEMKT: LBY ) +13% . Cyclerion Therapeutics (NASDAQ: CY...

Tocagen (NASDAQ: TOCA )  -82%  after two-part immunotherapy flunks brain cancer study. More news on: Tocagen Inc., Adverum Biotechnologies, Inc., Celyad SA, Stocks on the move Read more ...

Thinly traded nano cap Tocagen (NASDAQ: TOCA ) craters  67%  premarket on light volume (at this point) in reaction to unsuccessful results from a Phase 3 clinical trial, Toca 5 , evaluating Toca 511 & Toca FC in patients with high-grade glioma undergoing resection. More ne...

SAN DIEGO , Sept. 12, 2019 /PRNewswire/ --  Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced that the Toca 5 Phase 3, randomized, multi-center clinical trial evaluating Toca 511 & Toca FC in patients with recurrent high grade ...